Clinical Trials Logo

Clinical Trial Summary

This research is being done because the investigators are trying to examine the safety and effectiveness of this wound cleaning liquid, CACD (chlorine dioxide). The investigators are trying to see if this liquid has the ability to decrease infection rates and decrease the scarring effects from the healing process. In animal studies, CACD has been shown to decrease scar formation and decrease the risk of wound infections. CACD is also used for the treatment of burns to decrease infection rates and improve wound healing. CACD is not FDA approved for this specific use, but it is FDA and USDA approved for reducing bacterial contamination on meat and food products for human consumption. In addition, an investigational drug (IND) application has been submitted to the FDA for this study. The FDA has approved the use of this solution for this study.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01341041
Study type Interventional
Source Rhode Island Hospital
Contact
Status Completed
Phase Phase 0
Start date August 2004
Completion date June 2009

See also
  Status Clinical Trial Phase
Terminated NCT02937909 - A Study to Evaluate the Benefits of Using a Range of Wound Care Products From a Single Manufacturer N/A